Iterum Therapeutics to Present Data at IDWeek 2022

Rhea-AI Summary

Iterum Therapeutics plc (Nasdaq: ITRM) announced the presentation of two posters at IDWeek 2022, addressing critical advancements in tackling multi-drug resistant infections. The studies include data on the impact of asymptomatic bacteriuria in UTI treatment, and the efficacy of sulopenem against Bacillus anthracis. The conference runs from October 19-23 in Washington, D.C., with poster presentations scheduled for October 20 and 22. These findings will eventually be accessible on the company's website, emphasizing Iterum's commitment to developing novel antibiotics.

• Analysis of data from Phase 3 studies in uUTI and cUTI to assess the relevance of a positive urine culture in patients with no clinical symptoms after being treated for a UTI
  
  
• New data on the efficacy of sulopenem in an animal model of anthrax
  

DUBLIN, Ireland and CHICAGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that two posters will be presented at the Infectious Disease Society of America’s IDWeek 2022.

The hybrid conference will be held from October 19-23 at the Walter E. Washington Convention Center in Washington, D.C. Posters will be available for registrants on the IDWeek Interactive Program and the IDWeek Mobile App starting on October 19, 8 a.m. ET. Onsite attendees can view posters from Oct. 20-22 from 8 a.m. to 6 p.m.

Data to be presented at IDWeek 2022 include:

Presentation Title: Impact of Asymptomatic Bacteriuria on Primary Efficacy Analyses in the Evaluation of Novel Antimicrobials for the Treatment of Patients with Urinary Tract Infection
Poster #: 227
Presenter: Steven Aronin
Time/Location: Thursday, October 20, 12:15 p.m. - 1:30 p.m. in Hall B+C

Presentation Title: Murine Efficacy Studies of Sulopenem Against Bacillus anthracis
Poster #: 1724
Presenter: Sailaja Puttagunta
Time/Location: Saturday, October 22, 12:15 p.m. - 1:30 p.m. in Hall B+C

These Posters will be made available on the Company’s website on the “Publications: Posters & Presentations” page under the “Our Science” tab once the conference ends.

About Iterum Therapeutics plc

Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum Therapeutics is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum Therapeutics has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications.

Investor Contact:
Judy Matthews
Chief Financial Officer
312-778-6073
IR@iterumtx.com

FAQ

What findings will Iterum Therapeutics present at IDWeek 2022 regarding uUTI and cUTI?

Iterum Therapeutics will present the impact of asymptomatic bacteriuria on the efficacy analysis in urinary tract infection treatments.

When is the IDWeek 2022 conference taking place?

IDWeek 2022 is scheduled from October 19 to October 23, 2022.

What is the significance of sulopenem in the context of the presentations?

Sulopenem is being studied for its efficacy against Bacillus anthracis and is part of Iterum's efforts to combat multi-drug resistant infections.

Where can I find the posters presented by Iterum Therapeutics after IDWeek 2022?

The posters will be available on Iterum's website under the 'Publications: Posters & Presentations' page once the conference concludes.

What does the Phase 3 study from Iterum Therapeutics focus on?

The Phase 3 study focuses on the relevance of positive urine cultures in patients with no clinical symptoms post UTI treatment.